"\u00DAloha ukazatel\u016F kostn\u00EDho metabolismu v hodnocen\u00ED myelomov\u00E9 kostn\u00ED nemoci"@cs . . "Ba\u010Dovsk\u00FD, Jaroslav" . "Pika, Tom\u00E1\u0161" . . "Mina\u0159\u00EDk, Ji\u0159\u00ED" . "The role of bone metabolism parameters in the assessment of myeloma bone disease"@en . . . "[25B20C75079A]" . . "RIV/61989592:15110/13:33145096" . . "Klinick\u00E1 biochemie a metabolismus" . . . "21(42)" . "15110" . "\u00DAloha ukazatel\u016F kostn\u00EDho metabolismu v hodnocen\u00ED myelomov\u00E9 kostn\u00ED nemoci" . . . . . . "The role of bone metabolism parameters in the assessment of myeloma bone disease"@en . . "4"^^ . . . "112438" . . "\u00DAloha ukazatel\u016F kostn\u00EDho metabolismu v hodnocen\u00ED myelomov\u00E9 kostn\u00ED nemoci"@cs . "CZ - \u010Cesk\u00E1 republika" . . "1210-7921" . "P(NT12451), P(NT14400)" . "\u0160\u010Dudla, Vlastimil" . . . "Petrov\u00E1, Pavla" . "6"^^ . "N\u00E1pln\u00ED sd\u011Blen\u00ED je pod\u00E1n\u00ED aktu\u00E1ln\u00ED informace o v\u00FDznmu vy\u0161et\u0159ov\u00E1n\u00ED ukazatel\u016F kostn\u00EDho metabolismu u mnoho\u010Detn\u00E9ho myelomu (MM). Hlub\u0161\u00ED pozornost je v\u011Bnov\u00E1na obecn\u00E9mu postaven\u00ED marker\u016F kostn\u00ED remodelace v hodnocen\u00ED myelomov\u00E9 kostn\u00ED nemoci (MKN) a ukazatel\u016F kostn\u00ED resorpce i novotvorby z hlediska jejich v\u00FDznamu pro klinickou praxi. Samostatn\u00E9 kapitoly jsou v\u011Bnov\u00E1ny vztahu marker\u016F kostn\u00ED resorpce a kostn\u00ED novotvorby k t\u00ED\u017Ei MKN, stupni pokro\u010Dilosti, aktivity a progn\u00F3zy MM a odli\u0161nostem mezi monoklon\u00E1ln\u00ED gamapati\u00ED nejist\u00E9ho v\u00FDznamu a MM. Zvl\u00E1\u0161tn\u00ED pozornost je v\u011Bnov\u00E1na nepochybn\u00E9mu p\u0159\u00EDnosu monitorov\u00E1n\u00ED marker\u016F osteoresorpce, zejm\u00E9na S-ICT/ a U-NTX a neuspokojiv\u00E9mu v\u00FDznamu ukazatel\u016F kostn\u00ED novotvorby, tj. S-bALP a S-osteokalcinu v pr\u016Fb\u011Bhu l\u00E9\u010Dby MM a antiresorp\u010Dn\u00ED terapie bisfosfon\u00E1ty. Stranou nez\u016Fstala ani informace o nov\u00FDch, perspektivn\u00EDch molekul\u00E1ch, maj\u00EDc\u00EDch vztah k procesu kostn\u00EDch zm\u011Bn u MM, tj. indexu RANKL/osteoprotegerin, Dickkopf-1 (DKK-1), activinu A a osteosklerostinu. Vy\u00FAst\u011Bn\u00EDm sd\u011Blen\u00ED je p\u0159ehled vhodn\u00FDch marker\u016F kostn\u00EDho obratu, doporu\u010Den\u00FDch pro pteby standardn\u00ED klinick\u00E9 praxe International Myeloma Working Group." . . . "RIV/61989592:15110/13:33145096!RIV14-MZ0-15110___" . . . "therapy; DKK-1; RANKL/osteoprotegerin; osteogenesis markers (S-bALP, S-osteocalcin); bone resorption markers (S-ICTP, U-NTX, S-TRACP-5b); myeloma bone disease; multiple myeloma"@en . "2" . "The aim of this contribution is to present up to date information regarding bone metabolism in multiple myeloma (MM) Special attention is dedicated to the general role of bone remodellation markers in the assessment of myeloma bone disease (MBD), ane the parameters of bone resorption and osteogenesis from the point of their significance in clinical practice. Individual chapters aim at the relationship of bone resorption and steogenesis markers to the severity of MBD, and to the stage, grade, activity and prognosis of multiple myeloma, and differences between monoclonal gammopathy of undetermined significance (MGUS) and MM. Interest is dedicated to the contribution, of monitoring of bone resorption markers, i.e. S-ICTP and U-NTX, and not very satisfactory significance of osteogenesis markers, i.e. S-bALP and S-osteocalcin in the course of MM treatment including anti-resorption treatment with bisphosphonates. We present information about new and perspective molecules involved in bone remodellation process in MM, i.e. RANKL/osteoprotegerin index, Dickkopf-1 (Dkk-1), activin-A and osteosclerostin. The outcome of the paper is the summary of convenient markers of bone metabolism, recommended for the use in standard clinical practice by International Myeloma Working Group."@en . "N\u00E1pln\u00ED sd\u011Blen\u00ED je pod\u00E1n\u00ED aktu\u00E1ln\u00ED informace o v\u00FDznmu vy\u0161et\u0159ov\u00E1n\u00ED ukazatel\u016F kostn\u00EDho metabolismu u mnoho\u010Detn\u00E9ho myelomu (MM). Hlub\u0161\u00ED pozornost je v\u011Bnov\u00E1na obecn\u00E9mu postaven\u00ED marker\u016F kostn\u00ED remodelace v hodnocen\u00ED myelomov\u00E9 kostn\u00ED nemoci (MKN) a ukazatel\u016F kostn\u00ED resorpce i novotvorby z hlediska jejich v\u00FDznamu pro klinickou praxi. Samostatn\u00E9 kapitoly jsou v\u011Bnov\u00E1ny vztahu marker\u016F kostn\u00ED resorpce a kostn\u00ED novotvorby k t\u00ED\u017Ei MKN, stupni pokro\u010Dilosti, aktivity a progn\u00F3zy MM a odli\u0161nostem mezi monoklon\u00E1ln\u00ED gamapati\u00ED nejist\u00E9ho v\u00FDznamu a MM. Zvl\u00E1\u0161tn\u00ED pozornost je v\u011Bnov\u00E1na nepochybn\u00E9mu p\u0159\u00EDnosu monitorov\u00E1n\u00ED marker\u016F osteoresorpce, zejm\u00E9na S-ICT/ a U-NTX a neuspokojiv\u00E9mu v\u00FDznamu ukazatel\u016F kostn\u00ED novotvorby, tj. S-bALP a S-osteokalcinu v pr\u016Fb\u011Bhu l\u00E9\u010Dby MM a antiresorp\u010Dn\u00ED terapie bisfosfon\u00E1ty. Stranou nez\u016Fstala ani informace o nov\u00FDch, perspektivn\u00EDch molekul\u00E1ch, maj\u00EDc\u00EDch vztah k procesu kostn\u00EDch zm\u011Bn u MM, tj. indexu RANKL/osteoprotegerin, Dickkopf-1 (DKK-1), activinu A a osteosklerostinu. Vy\u00FAst\u011Bn\u00EDm sd\u011Blen\u00ED je p\u0159ehled vhodn\u00FDch marker\u016F kostn\u00EDho obratu, doporu\u010Den\u00FDch pro pteby standardn\u00ED klinick\u00E9 praxe International Myeloma Working Group."@cs . . . "8"^^ . "Lochman, Pavel" . "\u00DAloha ukazatel\u016F kostn\u00EDho metabolismu v hodnocen\u00ED myelomov\u00E9 kostn\u00ED nemoci" . .